BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AVL-292: Phase Ia data

Avila Therapeutics Inc., Waltham, Mass.
Product: AVL-292
Business: Cancer
Molecular target: Bruton's tyrosine kinase (Btk)
Description: Covalent small molecule Bruton's...

Read the full 96 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >